

---

## The Hellenic Institute for the Study of Sepsis Announces the Successful Evaluation of the ImmunoSep Project by the European Commission

---

### A New Frontier in Personalized Immunotherapy for Sepsis

---

The Hellenic Institute for the Study of Sepsis (HISS) proudly announces the successful implementation and evaluation of the groundbreaking ImmunoSep project, as confirmed by three independent monitors from esteemed institutions including Lund University, Jagiellonian University, and the National Institute of Public Health NIH of Poland. The project, funded under the European Commission's Horizon 2020 program, has delivered transformative results in the fight against sepsis—a condition responsible for millions of deaths globally each year.

The ImmunoSep project is a Horizon 2020 grant co-ordinated by **Prof. Mihai G. Netea**

#### HISS Leadership

HISS is honoured to have played a central role in this transformative initiative leading 42 clinics and Universities from 6 EU countries enrolling a total of 281 patients. Major clinical partners complementing and contributing to this effort were:

1. STICHTING KATHOLIEKE UNIVERSITEIT, Nijmegen, the Netherlands (PI: Prof. P.Pickkers)
2. CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS, Lausanne, Switzerland (PI: Prof. T.Calandra)
3. Universitätsklinikum Jena, Germany (PI: Prof. M.Bauer)
4. ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, Netherlands (PI: Profs. A.Vlaar and W. J. Wiersinga)
5. UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCA, Romania (PI: Prof. M. Lupse)

Esteemed partners complementing and contributing to this effort were:

6. HOSPICES CIVILS DE LYON, France
7. RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN, Germany
8. CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH, Austria
9. TEL AVIV UNIVERSITY, Israel
10. BIOMERIEUX SA, France
11. BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE, France
12. THE UNIVERSITY OF READING, United Kingdom

### 13. EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH, Germany

The ImmunoSep project represents a leap forward in precision medicine, offering hope to millions of sepsis patients worldwide and HISS is grateful to the partners and the European Commission for their unwavering support.

#### **Exceptional Results and Impact**

The ImmunoSep project has fully achieved its objectives, as outlined in the Grant Agreement, including the development of a novel personalized immunotherapy approach. Highlights of the project's outcomes include:

- **Innovative Biomarkers:** Identification and validation of biomarkers enabling patient stratification based on immune responses (e.g., overinflammation or immunoparalysis).
- **Therapeutic Advancements:** The first successful clinical trial demonstrating the efficacy of personalized immunotherapy for sepsis patients.
- **Data Integration:** Comprehensive multi-omics analyses have laid the foundation for theranostic pipelines that integrate immunotype stratification and treatment prediction.

These results promise a profound impact on global healthcare systems by lowering sepsis mortality rates and creating a paradigm shift in treatment approaches for infectious and non-infectious diseases.

#### **Acknowledgment of Excellence**

The independent monitors highlighted the high quality and scientific significance of the project. They emphasized the robustness of the results, which have been disseminated effectively through 17 high-impact scientific publications and participation in leading conferences. The project has reached over 15,000 stakeholders, including healthcare professionals, policymakers, and the general public. More information on the project can be seen on its website: <https://www.immunosep.eu/>

#### **About HISS**

Hellenic Institute for the Study of Sepsis (HISS) is a leader in healthcare innovation, specializing in research, development, and implementation of cutting-edge medical solutions. Through projects like ImmunoSep, HISS is dedicated to advancing global healthcare standards and improving patient outcomes.